title: Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
abstract: Transfusional iron overload in patients with chronic anemias can result in multiple organ failure. Experience in the management of iron overload in patients with myelodysplastic syndromes is limited, as many do not receive chelation therapy due to short-life expectancy and the difficulties associated with the administration of the current reference standard chelator, deferoxamine. There have, however, been some reports of reduced transfusion requirement associated with chelation therapy in patients with myelodysplastic syndromes and myelofibrosis. Here, we discuss a patient with primary myelofibrosis and related transfusion-dependent anemia who received chelation therapy with the once-daily oral iron chelator, deferasirox. In addition to the reduced iron levels, the patient demonstrated an unexpected reduction in blood transfusion requirement, ultimately resulting in long-lasting transfusion-free survival.
authors: Unità Operativa Ematologia e Centro Trapianti Midollo Osseo, Ospedale Oncologico Armando Businco, Cagliari, Italy.
authors: Anna Angela
authors: AA
authors: Di Tucci
authors: Roberta
authors: R
authors: Murru
authors: Daniele
authors: D
authors: Alberti
authors: Bertrand
authors: B
authors: Rabault
authors: Simona
authors: S
authors: Deplano
authors: Emanuele
authors: E
authors: Angelucci
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D001803:Blood Transfusion; D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000628:therapy*
chemical_list: D007502:Iron Chelating Agents; D003676:Deferoxamine